Update: Human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals

Current Opinion in Oncology

Volumn 19, Issue 5, 2007, Pages 464-469

  Kojic, Erna Milunka ^a   Cu Uvin, Susan ^b  

^a MIRIAM HOSPITAL   (United States)

^b NONE

Author keywords

Anogenital pap smears; Highly active antiretroviral therapy; HIV; HPV

Indexed keywords

ANTIRETROVIRUS AGENT; CARRAGEENAN; FLUOROURACIL; HEAT SHOCK PROTEIN 65; IMIQUIMOD; INDINAVIR; LOPINAVIR; PLACEBO; TRICHLOROACETIC ACID; WART VIRUS VACCINE;

ANUS CANCER; CORRELATION FUNCTION; CYTOLOGY; EVALUATION; HEALTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERVENTION STUDY; MOLECULAR BIOLOGY; PERSISTENT INFECTION; POPULATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

HIV; HIV INFECTIONS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE;

EID: 34548402155     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282c8c84c     Document Type: Review

References (41)

1. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-690.
2. Sun XW, Ellerbrock TV, Lungu O, et al. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol 1995; 85 (5 Pt 1):680-686.
3. Silverberg MJ, Schneider MF, Silver B, et al. Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol 2006; 13:511-519. •• This paper is one of the few papers that addresses the issue of HPV serology in HIV-infected women. It also uses serial measurements of HPV antibody measurements to identify active HPV replication.
4. Bollen LJ, Chuachoowong R, Kilmarx PH, et al. Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: implications for future HPV immunization. Sex Transm Dis 2006; 33:259-264. • This paper assesses the HPV prevalence and distribution of different HPV types among HIV-infected pregnant women in Thailand.
5. Minkoff H, Xian LS, Watts DH, et al. Relationship of pregnancy to human papillomavirus among human immunodeficiency virus-infected women. Obstet Gynecol 2006; 108:953-960. • This paper describes the incident detection of HPV during pregnancy and compares the prevalence and copy number of HPV between pregnancy, prepregnancy and postpregnancy period in two of the largest cohorts of HIV-infected pregnant women in the United States. Among these women, incident detection of HPV was lower during pregnancy.
6. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-586.
7. Palefsky J. Human papillomavirus-related tumors in HIV. Curr Opin Oncol 2006; 18:463-468. • This excellent review of HPV related tumors in HIV-infected individuals includes a discussion on the utility of HPV vaccines in HIV-infected persons.
8. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95:1062-1071.
9. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006; 19:99-105. •• This is an elegant review of the mechanism of potentiation and biology of HPV-associated disease in HIV-infected individuals, providing an integrated model of the pathogenesis of HPV-related disease in HIV-infected hosts.
10. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. Aids 2006; 20:2337-2344. •• This paper describes to what extent different HPV types are associated with high-grade squamous intraepithelial lesions (HSIL) and cancer. In this meta-analysis, HPV-16 was underrepresented in HIV-positive women with HSIL, who showed a higher proportion of other and multiple HPV types compared with the general female population with HSIL.
11. Koshiol JE, Schroeder JC, Jamieson DJ, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006; 119:1623-1629. •• This report describes a detailed analysis of the time required to clear infections with specific HPV types among HIV-infected and HIV-uninfected women in The HIV Epidemiology Research Study (HERS). It was one of the first studies to examine the clearance of individual HPV types in both HIV-positive and negative women.
12. Luque AE, Jabeen M, Messing S, et al. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis 2006; 194:428-434. • This paper determined the prevalence of different HPV types in a cohort of HIV-infected women in Rochester, New York followed prospectively over 7 years. They found that high-risk types other than 16 and 18 are frequently detected among women with HIV infection and are often associated with abnormalities in cervical cytologic results.
13. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15:1274-1280. • In this study, the association between multiple HPV types and cervical lesions was examined among Brazilian women. The authors conclude that infections with multiple HPV types seem to act synergistically in cervical carcinogenesis.
14. Lillo FB, Uberti-Foppa C. Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women. J Antimicrob Chemother 2006; 57:810-814. •• This paper is one of the few papers correlating HPV infection and viral load with the severity of cervical disease and the use of HPV viral load as a possible risk marker in HIV-infected subjects.
15. Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection on atypical squamous cells of undetermined significance. Clin Infect Dis 2006; 42:855-861. • This study reaffirmed the higher incidence of atypical cells of undetermined significance (ASCUS) in HIV-infected women and shows that women with ASCUS are more likely to have progression to squamous intraepithelial lesions on a Pap smear. This gives empirical support to performing colposcopies on women with any level of cervical cytologic abnormalities.
16. Jamieson DJ, Paramsothy P, Cu-Uvin S, Duerr A, Group HIVERS. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol 2006; 107:1023-1028. •• This study confirmed the multicentric nature of HPV infection in HIV-infected women highlighting the need for a more thorough gynecological examination and for colposcopies in HIV-infected women.
17. Chalermchockcharoenkit A, Sirimai K, Chaisilwattana P. High prevalence of cervical squamous cell abnormalities among HIV-infected women with immunological AIDS-defining illnesses. J Obstet Gynaecol Res 2006; 32:324-329. • This paper shows a high prevalence of squamous cell abnormalities in HIV-infected women by postpartum Pap smears in Thailand. The prevalence is lower, however, compared with women in the Unites States, possibly reflecting a difference in risk characteristics among Thai women.
18. •], the prevalence of HPV related squamous intraepithelial lesions among HIV-infected Zambian women is one of the highest reported in any population worldwide.
19. Moodley JR, Hoffman M, Carrara H, et al. HIV and preneoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 2006; 6:135. • This study confirmed the high prevalence of HPV and squamous intraepithelial lesions in an African population, but did not demonstrate an excess risk of invasive cervical cancer.
20. Hawes SE, Critchlow CW, Sow PS, et al. Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl Cancer Inst 2006; 98:100-109. • This paper highlights the importance of HPV persistence in cervical intraepithelial neoplasia and is one of the few papers to include HIV-2 infection in the analyses.
21. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547-551.
22. Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15:2157-2164.
23. Del Mistro A, Bertorelle R, Franzetti M, et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 2004; 38:737-742.
24. Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. Aids 2002; 16:1799-1802.
25. Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005; 40:451-455.
26. Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101:281-288.
27. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-1510.
28. Cress RD, Holly EA. Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973-1999. Prev Med 2003; 36:555-560.
29. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19:1407-1414.
30. Sirera G, Videla S, Pinol M, et al. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS 2006; 20:1201-1204. •• This paper is one of the few papers published in 2006 describing simultaneous HPV infection at different sites in the same individual. The authors describe a high HPV prevalence in anus, penis and mouth.
31. Chiao EY, Giordano TP, Palefsky JM, et al. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43:223-233. • This paper reviews the utility of anal PAP smear screening of HIV-infected individuals in the era of effective antiretroviral therapy. This review reveals that no studies have found a statistically significant difference in the incidence of anal cancers in the pre-HAART era versus the HAART era.
32. Fox PA. Human papillomavirus and anal intraepithelial neoplasia. Curr Opin Infect Dis 2006; 19:62-66. • Here, the issue of HPV and anal intraepithelial lesions is addressed. Low-grade lesions frequently resolve, but high-grade lesions are more stable.
33. Gervaz P, Hirschel B, Morel P. Molecular biology of squamous cell carcinoma of the anus. Br J Surg 2006; 93:531-538. •• This paper points out a different mechanism for the rapid progression from HPV infection toward invasive carcinoma among those with HIV infection.
34. Palefsky JM, Berry JM, Jay N, et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 2006; 20:1151-1155. • This paper describes a novel treatment of high-grade anal intraepithelial neoplasia (HGAIN) using a therapeutic vaccine. It is a proof of concept for a novel therapeutic vaccine as a treatment for HGAIN.
35. Kreuter A, Brockmeyer NH, Weissenborn SJ, et al. 5% imiquimod suppositories decrease the DNA load of intra-anal HPV types 6 and 11 in HIV-infected men after surgical ablation of condylomata acuminata. Arch Dermatol 2006; 142:243-244.
36. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
37. Viscidi RP, Kotloff KL, Clayman B, et al. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 1997; 4:122-126.
38. Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002; 186:21-27.
39. Fakruddin JM, Lempicki RA, Gorelick RJ, et al. Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood 2007; 109:1841-1849. • This in-vitro study evaluated the effect of HPV virus like particles (VLP) on HIV replication in cells. The authors found that VLPs induced a novel anti-HIV cytokine, giving insight into immunologic control of HIV.
40. Buck CB, Thompson CD, Roberts JN, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006; 2:e69. • This study showed that carrageenan can block HPV infection, raising a question of evaluating its use as a topical microbicide against HPV infection.
41. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006; 11:813-825. •• This study is important because many antiretroviral regimens contain protease inhibitors. Here, protease inhibitors induced toxicity of HPV-transformed cervical carcinoma cells forming a basis of a topically applied treatment of HPV-related premalignant lesions.